

CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR

Statement of Cash Flows For the Year Ended June 30, 2021

26,072,247

2021 **CASH FLOWS FROM OPERATING ACTIVITIES:** Tuition and fees 51,763,206 Federal appropriations Grants and contracts 663,467,044 Sales and services of educational departments 8,465,015 Hospital income Auxiliary enterprise receipts 6,478,661 Payments for employee compensation (350,075,950)Payments for benefits (68,914,572)Payments for utilities (12,420,136)Payments for supplies and services (341,707,992) Payments for scholarship and fellowships (4,571,841)Loans to students (1,507,144)Collection of loans to students 970,428 Other receipts 8,303,177 Net cash used by operating activities (39,750,104) **CASH FLOWS FROM NONCAPITAL FINANCING ACTIVITIES:** 81,548,890 State appropriations Gifts and grants for other than capital purposes 48,481,316 Private gifts for endowment purposes 920,000 **TOPS** receipts 2,235,735 **TOPS** disbursements (2,229,300)**FEMA** receipts **FEMA** disbursements ARRA receipts Direct lending receipts 68,570,271 Direct lending disbursements (68,573,911)**CARES Receipts** 5,750,860 **CARES Disbursements** (5,750,860)Implicit loan to/from other campuses Other receipts 118,845 Net cash provided by noncapital financing activities \$ 131,071,846 **CASH FLOWS FROM CAPITAL FINANCING ACTIVITIES:** Proceeds from issuance of debt Capital gifts and grants received 12,000,000 Purchase of capital assets (66,656,344)Principal paid on capital debt and leases (737,088)Interest paid on capital debt and leases (423,406)Refunding of bonds Bond issuance cost Deposits with trustees Other uses (20,129)Net cash used by capital financing activities \$ (55,836,967)**CASH FLOWS FROM INVESTING ACTIVITIES:** Proceeds from sales and maturities of investments Interest received on investments 3,499,874 Purchase of investments 20,865 Net cash provided by investing activities Ś 3,520,739 **NET DECREASE IN CASH AND CASH EQUIVALENTS** 39,005,514



Statement of Cash Flows For the Year Ended June 30, 2021

2021

CASH AND CASH EQUIVALENTS AT END OF YEAR	\$	65,077,761
RECONCILIATION OF OPERATING LOSS TO NET CASH USED BY OPERATING		
ACTIVITIES:		
Operating loss	\$	(52,637,599)
Adjustments to reconcile operating loss to net cash used by operating		
activities:		
Depreciation expense		23,245,969
Non-employer contributing entity revenue		1,194,374
Changes in assets, deferred outflows,		
liabilities, and deferred inflows:		
(Increase)/Decrease in accounts receivable, net		(70,766,295)
(Increase)/Decrease in inventories		83,193
(Increase)/Decrease in prepaid expenses and other		6,493,789
(Increase)/Decrease in notes receivable		(536,716)
(Increase)/Decrease in deferred outflows related to OPEB		2,709,812
(Increase)/Decrease in deferred outflows related to pensions		(32,835,011)
(Increase)/Decrease in other assets		-
Increase/(Decrease) in accounts payable and accrued liabilities		23,702,289
Increase/(Decrease) in unearned revenue		924,947
Increase/(Decrease) in amounts held in custody for others		(123,091)
Increase/(Decrease) in compensated absences		245,279
Increase/(Decrease) in OPEB liability		13,884,851
Increase/(Decrease) in net pension liability		40,142,724
Increase/(Decrease) in deferred inflows related to OPEB		(8,080,286)
Increase/(Decrease) in deferred inflows related to pensions		(16,831,963)
Increase/(Decrease) in other liabilities		29,433,630
Net cash used by operating activities	\$	(39,750,104)
RECONCILIATION OF CASH AND CASH EQUIVALENTS TO THE STATEMENT OF		
NET POSITION:		
Cash and cash equivalents classified as current assets	\$	65,077,761
Cash and cash equivalents classified as noncurrent assets		-
Cash and cash equivalents at end of the year	\$	65,077,761
SCHEDULE OF NONCASH INVESTING, CAPITAL, AND FINANCING ACTIVITIES:		
Capital appropriations	\$	20,804,609
Amortized borrowing expense		
Increase/(Decrease) in fair market value of assets		13,129,924
Non-employer contributing entity revenue		1,194,374
Capital gifts and grants		83,152
Transfers/disposal of capital assets		(109,586)
	\$	35,102,473